PARIS: French company Carmat confirmed on Monday that it had fitted a second patient with one of its artificial hearts and would continue its clinical trials on two more patients.

Carmat's device, which mimicks nature's work using biological materials and sensors, is designed to serve not as a bridge to a heart transplant but as a permanent implant, extending life for terminally ill patients who cannot hope for a real organ, because they are too old or donors are scarce.

Shares in Carmat rose as much as 19 percent on Friday after French media reported that doctors had implanted an artificial heart made by the company for a second time. The stock was up 2.6 percent at 0737 GMT.

Source: APP